Evidence map›Paper›PMID 38310464›Full record

ArticleCurrent cancer drug targets2024

You Wu, Fenglin Zhang, Panling Xu, Ping Li

Abstract read
PubMed Publisher
In one paragraph

Article in Current cancer drug targets, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.9field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

You WuOncology Department of Integrated Traditional Chinese and Western Medicine, The First Affiliated Hospital of Anhui Medical University, 230022, Hefei, Anhui, China.ORCID 0000-0002-0896-4475
Fenglin ZhangOncology Department of Integrated Traditional Chinese and Western Medicine, The First Affiliated Hospital of Anhui Medical University, 230022, Hefei, Anhui, China.ORCID 0009-0004-7244-2913
Panling XuOncology Department of Integrated Traditional Chinese and Western Medicine, The First Affiliated Hospital of Anhui Medical University, 230022, Hefei, Anhui, China.ORCID 0000-0003-1592-5527
Ping LiOncology Department of Integrated Traditional Chinese and Western Medicine, The First Affiliated Hospital of Anhui Medical University, 230022, Hefei, Anhui, China.ORCID 0000-0003-0958-6784
Anhui Medical University · CN

Funding

Anhui Provincial Key Research and Development Plan 202104a07020021
6 · The paper itself

Abstract

introductionThe purpose of this research was to settle the role of brucine in pancreatic ductal adenocarcinoma (PDAC) and the mechanisms involved.

methodsThe findings of this study suggest that brucine exerts inhibitory effects on cell growth, clonogenicity, and invasive potential of Panc02 and Mia Paca-2 cells. These effects may be linked to an increase in apoptotic-prone cell population.

resultsGene sequencing data suggests that these effects are mediated through the induction of apoptosis. Experimental evidence further supports the notion that brucine reduces mitochondrial membrane potential and upregulates Bax expression while downregulating Bcl-2 expression. These effects are believed to be a result of brucine-mediated suppression of PI3K/Akt activity, which serves as a regulatory factor of mTOR, Bax, and Bcl-2. Suppression of PI3K activity enhances the tumor-suppressing effects of brucine.

conclusionOverall, these findings suggest that brucine has therapeutic potential as a remedy option for PDAC.

Indexed as

ApoptosisCarcinoma, Pancreatic DuctalMitochondriaPancreatic NeoplasmsStrychnineCell Line, TumorCell ProliferationHumansMembrane Potential, MitochondrialPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktSignal TransductionbrucinePhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktStrychnineapoptosisapoptotic- prone cell population.brucinemitochondria membrane potentialPancreatic ductal adenocarcinomaPI3K/ AKT

Identifiers

PMID38310464
OpenAlexW4391522330

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.